ePrints

Considerations for the cure assumption in a NICE Single Technology Appraisal of nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small cell lung cancer: Evidence Assessment Group perspective

Lookup NU author(s): Giovany Orozco LealORCiD, Eugenie Johnson, Dr Sedighe Hosseinijebeli, Tomos Robinson, Tara HomerORCiD, Claire EastaughORCiD, Dr Louise TannerORCiD, Dr Nick MeaderORCiD, Dr Ryan KennyORCiD, Sheila WallaceORCiD, Stephen RiceORCiD

Downloads

• Accepted version [.pdf]

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).

Publication metadata

Author(s): Orozco Leal G, Johnson EE, Hosseinijebeli S, Robinson T, Homer T, Eastaugh C, Richmond C, Tanner L, Meader N, Kenny R, Wallace SA, Rice S

Publication type: Article

Publication status: Published

Journal: PharmacoEconomics

Year: 2023

Volume: 42

Pages: 133-136

Online publication date: 20/11/2023

Acceptance date: 09/10/2023

Date deposited: 11/12/2023

ISSN (print): 1170-7690

Publisher: Springer

URL: https://doi.org/10.1007/s40273-023-01328-w

DOI: 10.1007/s40273-023-01328-w

ePrints DOI: 10.57711/k6kc-8x77

Altmetrics

Funding

Share